Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals
January 16, 2015 at 08:58 AM EST
Investors cheered the Depomed Inc (NASDAQ: DEPO) decision to acquire the U.S. rights to the NUCYNTA franchise as the stock traded 8 ...
